Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Antiplatelet therapy in peripheral artery disease.

Violi F, Basili S, Berger JS, Hiatt WR.

Handb Exp Pharmacol. 2012;(210):547-63. doi: 10.1007/978-3-642-29423-5_22. Review.

PMID:
22918746
2.

Is aspirin still the drug of choice for management of patients with peripheral arterial disease?

Poredos P, Jezovnik MK.

Vasa. 2013 Mar;42(2):88-95. doi: 10.1024/0301-1526/a000251. Review.

PMID:
23485835
3.

[The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients].

Drouet L, Bal dit Sollier C, Henry P.

Drugs. 2010 Nov 1;70 Suppl 1:9-14. doi: 10.2165/00000005-000000000-00000. Review. Japanese.

PMID:
20977287
4.

Peripheral arterial disease: pathophysiology, risk factors, and role of antithrombotic therapy.

Bradberry JC.

J Am Pharm Assoc (2003). 2004 Mar-Apr;44(2 Suppl 1):S37-44; quiz S44-5. Review.

PMID:
15095934
5.
6.

Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors.

Coccheri S.

Drugs. 2010 May 7;70(7):887-908. doi: 10.2165/11536000-000000000-00000. Review.

PMID:
20426498
7.
8.

Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.

Zusman RM, Chesebro JH, Comerota A, Hartmann JR, Massin EK, Raps E, Wolf PA.

Clin Cardiol. 1999 Sep;22(9):559-73. Review.

9.

Rationale for the use of platelet aggregation inhibitors in PAD patients.

Agnelli G.

Vasc Med. 2001;6(3 Suppl):13-5. Review.

PMID:
11789961
10.
11.

Antiplatelet therapy in peripheral arterial disease.

Aronow WS.

Curr Drug Targets Cardiovasc Haematol Disord. 2004 Sep;4(3):265-7. Review.

PMID:
15379619
12.

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. Review.

13.

Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care.

Garimella PS, Hart PD, O'Hare A, DeLoach S, Herzog CA, Hirsch AT.

Am J Kidney Dis. 2012 Oct;60(4):641-54. doi: 10.1053/j.ajkd.2012.02.340. Epub 2012 May 5. Review.

PMID:
22560831
14.

Role of antiplatelet drugs in the prevention of cardiovascular events.

Tendera M, Wojakowski W.

Thromb Res. 2003 Jun 15;110(5-6):355-9. Review.

PMID:
14592562
15.

Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.

Mehta SR, Yusuf S.

J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):79S-88S. Review.

PMID:
12644345
16.

Evidence with antiplatelet therapy and ADP-receptor antagonists.

Easton JD.

Cerebrovasc Dis. 2003;16 Suppl 1:20-6. Review.

PMID:
12698015
17.

Asymptomatic peripheral artery disease and antiplatelet management.

Raparelli V, Proietti M, Napoleone L, Bucci T, Talerico G, Pignataro FS, Basili S.

Vasa. 2014 Sep;43(5):309-25. doi: 10.1024/0301-1526/a000369. Review.

PMID:
25147008
18.
19.

Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?

Mohler ER 3rd.

Catheter Cardiovasc Interv. 2009 Jul 1;74 Suppl 1:S1-6. doi: 10.1002/ccd.21995. Review.

PMID:
19213065
20.

Antithrombotic drugs for the secondary prevention of ischemic stroke.

Nenci GG, Goracci S.

Ann Ital Med Int. 2000 Oct-Dec;15(4):282-90. Review.

PMID:
11202630
Items per page

Supplemental Content

Write to the Help Desk